MO SB1454

Expands Missouri's "Right to Try" law to include patients with life-threatening or severely debilitating conditions, not just terminal illnesses, allowing access to investigational drugs, biological products, or devices that have completed phase one clinical trials

Removes the exclusion of Schedule I controlled substances from the definition of investigational drugs that may be made available to eligible patients

Requires eligible patients to have considered all FDA-approved treatment options, received a physician's recommendation, and provided written informed consent before accessing investigational treatments

Protects physicians from state licensing actions and Medicare certification penalties based solely on recommending investigational treatments to eligible patients

Shields manufacturers, distributors, prescribers, and others from state law liability for investigational drug use, except in cases of gross negligence or willful misconduct